Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.66 |
| ▸ | CA1 | P00915 | 15/20 | 0.66 |
| ▸ | CA2 | P00918 | 15/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8015867 | 0.90 | PTGS2 (0.65) | CA9CA1CA2PTGS2 | |
| SCHEMBL5798707 | 0.90 | CA9 (0.65) | CA9CA1CA2PTGS2 | |
| SCHEMBL8688892 | 0.88 | PTGS2 (0.51) | CA9CA1CA2PTGS2 | |
| SCHEMBL8638297 | 0.88 | CA1 (0.58) | CA9CA1CA2PTGS2 | |
| SCHEMBL8689248 | 0.87 | CA9 (0.67) | CA9CA1CA2PTGS2 | |
| SCHEMBL8688836 | 0.87 | PTGS2 (0.66) | CA9CA1CA2PTGS2 | |
| SCHEMBL8677688 | 0.86 | CA1 (0.52) | CA9CA1CA2PTGS2 | |
| SCHEMBL7773923 | 0.84 | PTGS2 (0.52) | CA9CA1CA2PTGS2 | |
| SCHEMBL8693636 | 0.84 | PTGS2 (0.47) | CA9CA1CA2PTGS2 | |
| SCHEMBL8689456 | 0.84 | PTGS2 (0.47) | CA9CA1CA2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-5760068-A | NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS | G.D. SEARLE & CO. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5756529-A | ANTIINFLAMMATORY | G.D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | IRAK2, IRAK4, IRAK3 | CA9 3268/4885CA1 4557/4885CA2 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.